<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Qiu ZY</submitter><funding>National Natural Science Foundation of China</funding><pubmed_abstract>Cardiac remodeling is an important mechanism of heart failure, which frequently results from leukocyte infiltration. Vascular cellular adhesion molecule-1 (VCAM-1) plays a critical role in leukocyte adhesion and transmigration. However, the importance of VCAM-1 in the development of angiotensin II (Ang II)-induced cardiac remodeling remains unclear. Wild-type (WT) mice were infused with Ang II (1,000 ng/kg/min) for 14 days and simultaneously treated with VCAM-1 neutralizing antibody (0.1 or 0.2 mg) or IgG control. Systolic blood pressure (SBP) and cardiac function were detected by a tail-cuff and echocardiography. Cardiac remodeling was evaluated by histological staining. Adhesion and migration of bone marrow macrophages (BMMs) were evaluated &lt;i>in vitro&lt;/i>. Our results indicated that VCAM-1 levels were increased in the serum of patients with heart failure (HF) and the hearts of Ang II-infused mice. Furthermore, Ang II-caused hypertension, cardiac dysfunction, hypertrophy, fibrosis, infiltration of VLA-4+ BMMs and oxidative stress were dose-dependently attenuated in mice administered VCAM-1 neutralizing antibody. In addition, blocking VCAM-1 markedly alleviated Ang II-induced BMMs adhesion and migration, therefore inhibited cardiomyocyte hypertrophy and fibroblast activation. In conclusion, the data reveal that blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding VLA-4+ macrophage infiltration. Selective blockage of VCAM-1 may be a novel therapeutic strategy for hypertensive cardiac diseases.</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1058268</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9713306</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding macrophage infiltration.</pubmed_title><pmcid>PMC9713306</pmcid><pubmed_authors>Qiu ZY</pubmed_authors><pubmed_authors>Bai J</pubmed_authors><pubmed_authors>Yu WJ</pubmed_authors><pubmed_authors>Lin QY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding macrophage infiltration.</name><description>Cardiac remodeling is an important mechanism of heart failure, which frequently results from leukocyte infiltration. Vascular cellular adhesion molecule-1 (VCAM-1) plays a critical role in leukocyte adhesion and transmigration. However, the importance of VCAM-1 in the development of angiotensin II (Ang II)-induced cardiac remodeling remains unclear. Wild-type (WT) mice were infused with Ang II (1,000 ng/kg/min) for 14 days and simultaneously treated with VCAM-1 neutralizing antibody (0.1 or 0.2 mg) or IgG control. Systolic blood pressure (SBP) and cardiac function were detected by a tail-cuff and echocardiography. Cardiac remodeling was evaluated by histological staining. Adhesion and migration of bone marrow macrophages (BMMs) were evaluated &lt;i>in vitro&lt;/i>. Our results indicated that VCAM-1 levels were increased in the serum of patients with heart failure (HF) and the hearts of Ang II-infused mice. Furthermore, Ang II-caused hypertension, cardiac dysfunction, hypertrophy, fibrosis, infiltration of VLA-4+ BMMs and oxidative stress were dose-dependently attenuated in mice administered VCAM-1 neutralizing antibody. In addition, blocking VCAM-1 markedly alleviated Ang II-induced BMMs adhesion and migration, therefore inhibited cardiomyocyte hypertrophy and fibroblast activation. In conclusion, the data reveal that blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding VLA-4+ macrophage infiltration. Selective blockage of VCAM-1 may be a novel therapeutic strategy for hypertensive cardiac diseases.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-06-18T03:11:41.126Z</modification><creation>2025-02-19T04:34:23.298Z</creation></dates><accession>S-EPMC9713306</accession><cross_references><pubmed>36467095</pubmed><doi>10.3389/fphar.2022.1058268</doi></cross_references></HashMap>